Sun Pharma Advanced Research (SPARC), a pharma research & drug discovery company, witnessed a sharp rise in share price on Tuesday after the US Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops.

While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA.

Shares of the company  are trading at Rs 204, up Rs 22.45, or 12.37%  at the Bombay Stock Exchange (BSE) on Tuesday at 10:15 a.m. The scrip has touched an intra-day high of Rs 208.50 and low of Rs 190. The total volume of shares traded at the BSE is 668,677.